[Optimizing epilepsy therapy in children and adolescents with lamotrigine]

H Siemes1, U Brandl, C Helmstädter

  • 1Fachklinik Hohenstücken, Neurologisches Rehabilitationszentrum für Kinder und Jugendliche. hartmut.siemes@t-online.de

Klinische Padiatrie
|July 21, 2005
PubMed

Insights

Lamotrigine is an effective antiepileptic drug for children and adolescents with various epilepsies. It offers good tolerability, cognitive function preservation, and potential mood-stabilizing benefits.

Area of Science:

  • Pediatric Neurology
  • Pharmacology

Background:

  • Lamotrigine is a widely used antiepileptic drug (AED) for pediatric epilepsy.
  • Its efficacy in focal and generalized epilepsies, including specific syndromes, is well-established.

Purpose of the Study:

  • To review the efficacy and tolerability of lamotrigine in children and adolescents.
  • To highlight its use in specific epilepsy types and age groups, including infants.

Main Methods:

  • Review of existing clinical data and studies on lamotrigine in pediatric populations.
  • Analysis of safety profiles, including cognitive effects and skin reactions.
  • Consideration of combination therapy and preclinical findings.

Main Results:

  • Lamotrigine demonstrates broad efficacy in mono- and add-on therapy for pediatric epilepsies.
  • Favorable tolerability profile includes no weight gain, preserved cognitive function, and reduced skin rash incidence with updated guidelines.
  • Effective in various epilepsy types like tuberous sclerosis, juvenile neuronal lipofuscinosis, Rett syndrome, and in children under two years.

Conclusions:

  • Lamotrigine is a primary choice AED for older children and adolescents due to its efficacy and tolerability.
  • Combination with valproate is effective for difficult-to-treat epilepsies.
  • Preclinical data suggest antiepileptogenic and neuroprotective effects, with mood-stabilizing properties improving quality of life.

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...